Stock Events

Stock Events

Evolus 

$4.03
27
-$0.28-6.5% Thursday 20:00

Statistics

Day High
4.16
Day Low
3.99
52W High
12.28
52W Low
3.86
Volume
834,599
Avg. Volume
1,328,262
Mkt Cap
261.22M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.25
-0.15
-0.05
0.05
Expected EPS
-0.110317
Actual EPS
N/A

Financials

-18.94%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
532.55MRevenue
-100.84MNet Income

Analyst Ratings

$15.50Average Price Target
The highest estimate is 19.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EOLS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., through its acquisition of companies and products, competes in the aesthetics and dermatology space, potentially overlapping with Evolus's market.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, a large pharmaceutical company, has a diverse portfolio that includes products competing in the aesthetics space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, with its broad range of healthcare products, competes in various segments, including those that overlap with Evolus's interests.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, after acquiring Allergan, directly competes with Evolus in the cosmetic injectable market, particularly with its Botox product.
State Street Global Allocation
GAL
Mkt Cap0
Galderma, a company specializing in dermatological treatments, offers a range of products that compete in the same space as Evolus's offerings.
Revolve Group
RVLV
Mkt Cap1.58B
Revolve, while primarily known for its fashion retail, has ventured into beauty and skincare products that could indirectly compete with Evolus.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its wide range of healthcare products, has interests in the dermatology and aesthetics market, competing with Evolus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries, with its generic and specialty medicines, competes in the broader pharmaceutical market, including areas relevant to Evolus.
Novartis
NVS
Mkt Cap237.61B
Novartis, a global healthcare company, has a diverse portfolio that includes dermatology and aesthetics, competing with Evolus in certain markets.

About

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Show more...
CEO
Mr. David Moatazedi
Employees
372
Country
US
ISIN
US30052C1071

Listings

LSE
GB
0K16.LSE
F
DE
EVL.F
XNAS
US
EOLS
BOATS
BOATS
EOLS.BOATS

0 Comments

Share your thoughts

FAQ

What is Evolus stock price today?▼
The current price of EOLS is $4.03 USD — it has decreased by -6.5% in the past 24 hours. Watch Evolus stock price performance more closely on the chart.
What is Evolus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Evolus stocks are traded under the ticker EOLS.
Is Evolus stock price growing?▼
EOLS stock has risen by +0.5% compared to the previous week, the month change is a -2.42% fall, over the last year Evolus has showed a -64.62% decrease.
What is Evolus market cap?▼
Today Evolus has the market capitalization of 261.22M
When is the next Evolus earnings date?▼
Evolus is going to release the next earnings report on May 12, 2026.
What were Evolus earnings last quarter?▼
EOLS earnings for the last quarter are 0.04 USD per share, whereas the estimation was 0.05 USD resulting in a -2.09% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Evolus revenue for the last year?▼
Evolus revenue for the last year amounts to 532.55M USD.
What is Evolus net income for the last year?▼
EOLS net income for the last year is -100.84M USD.
How many employees does Evolus have?▼
As of April 03, 2026, the company has 372 employees.
In which sector is Evolus located?▼
Evolus operates in the Health Care sector.
When did Evolus complete a stock split?▼
Evolus has not had any recent stock splits.
Where is Evolus headquartered?▼
Evolus is headquartered in Newport Beach, US.